베인은 홈페이지 기능 및 성능 개선을 위해 쿠키를 사용합니다. 이와 관련된 더 많은 정보는 개인정보 메뉴에서 확인하실 수 있습니다. 이 웹사이트를 계속 사용하시면 쿠키 사용에 동의하신 것으로 간주됩니다. 

BioPharma Dive

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

  • 2016년1월4일
  • 읽기 소요시간

BioPharma Dive

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

BioPharma Dive tapped into the expertise of top thought leaders in the industry to get their takes on what comes next in pricing, M&As, drug development, transparency and much more. "Bain has demonstrated how biopharma leaders have created the most shareholder value by focusing on a few, sustainable leadership positions in Product Categories (distinct from Therapeutic Areas)," said Ashish Singh, the leader of Bain & Company's Global Healthcare practice. "This focused strategy of Category Leadership has been proven to provide superior returns on investment in R&D and commercial."